Atriva’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Atriva is a biopharmaceutical company that develops and commercializes antiviral therapeutics for the treatment of influenza and COVID-19. Read more

Rainer Lichtenberger's photo - CEO of Atriva

CEO

Rainer Lichtenberger

CEO Approval Rating

76/100

Founded:

2015

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NanoViricides is seen as one of Atriva's biggest rivals. NanoViricides was founded in 2005 in Shelton, Connecticut. NanoViricides operates in the Pharmaceuticals industry. NanoViricides generates $2.6M more revenue than Atriva.

Chimerix is one of Atriva's top competitors. Chimerix was founded in 2000, and its headquarters is in Durham, North Carolina. Chimerix operates in the Pharmaceuticals industry. Chimerix has 28 more employees than Atriva.

Visterra is one of Atriva's top rivals. Visterra was founded in 2007, and is headquartered in Waltham, Massachusetts. Like Atriva, Visterra also operates in the Biotechnology space. Visterra generates $1M more revenue vs. Atriva.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $2M a good estimate for Atriva's revenue?

Acquisitions

No recent acquisitions found related to Atriva

Atriva Funding History

$0$10.2M

Since Atriva was founded in 2015, it has participated in 4 rounds of funding. In total Atriva has raised $10.2M. Atriva's last funding round was on Aug 2020 for a total of $10.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2020
$10.2M

Meneldor B.V.

Series A
Jan 2019
--
Seed
Sep 2017
--
Seed
Feb 2017
--

Total Funding: $10.2M

Since Atriva was founded in 2015, it has participated in 4 rounds of funding. In total Atriva has raised $10.2M. Atriva's last funding round was on Aug 2020 for a total of $10.2M

Investments

No recent investments found related to Atriva

Atriva News

January 8, 2020FinanzNachrichten

Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

TÜBINGEN, GERMANY / ACCESSWIRE / January 8, 2020 / Atriva Therapeutics GmbH, a clinical stage biophar... See more »
November 8, 2019MarketScreener

Reports Results of ATR-002 Phase I Clinical Trial

(marketscreener.com) DGAP-News: Atriva Therapeutics GmbH / Key word(s): Study results Atriva Therapeu... See more »
May 18, 2019Pharmabiz

Atriva Therapeutics begins patient dosing in phase 1 trial of ATR─002 to treat influenza virus infections

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host─targeting an... See more »
May 16, 20194-traders

Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza

(marketscreener.com) DGAP-News: Atriva Therapeutics GmbH / Key word(s): Study Atriva Therapeutics Sta... See more »
February 14, 2019BioSpace

SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe

Arvelle Therapeutics to receive rights to develop and commercialize cenobamate, an investigational an... See more »
January 11, 2019FinSMEs

Atriva Therapeutics Raises Initial Series A Funding

Atriva Therapeutics, a Tübingen, Germany-based biopharmaceutical company developing host-targeting an... See more »
August 5, 2018BioPortfolio

Atriva Therapeutics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250

SummaryAtriva Therapeutics GmbH Atriva Therapeutics develops antiviral therapies against seasonal and... See more »

Atriva Press Releases

Headquarters

Eisenbahnstr. 1

Tuebingen, Baden-Württemberg72072

49-7071-859-7673

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Atriva is a biopharmaceutical company that develops and commercializes antiviral therapeutics for the treatment of influenza and COVID-19. Atriva was founded in 2015. Atriva's headquarters is located in Tuebingen, Baden-Württemberg, DE 72072. It has r...

CEO

Atriva's CEO, Rainer Lichtenberger, currently has an approval rating of 76%. Atriva's primary competitors are NanoViricides, Chimerix & Visterra.

Website

atriva-therapeutics.com

Frequently Asked Questions about Atriva

  1. When was Atriva founded?

    Atriva was founded in 2015
  2. Who is Atriva's CEO?

    Atriva's CEO is Rainer Lichtenberger
  3. How much revenue does Atriva generate?

    Atriva generates $2M in revenue
  4. How much funding does Atriva have?

    Atriva has historically raised $10.2M in funding
  1. Where is Atriva's headquarters?

    Atriva's headquarters is in Tuebingen Baden-Württemberg, DE
  2. How many employees does Atriva have?

    Atriva has 15 employees
  3. What sector does Atriva operate in?

    Atriva is in Biotechnology
  4. Who are Atriva's competitors?

    Atriva's top competitors are NanoViricides, Chimerix, Visterra